Terms: = Lung cancer AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Clinical Outcome
3 results:
1. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
2. Expression Of Intracellular Components of the NF-κB Alternative Pathway (NF-κB2, RelB, NIK and bcl3) is Associated With clinical outcome of NSCLC Patients.
Dimitrakopoulos FD; Antonacopoulou AG; Kottorou AE; Panagopoulos N; Kalofonou F; Sampsonas F; Scopa C; Kalofonou M; Koutras A; Makatsoris T; Dougenis D; Papadaki H; Brock M; Kalofonos HP
Sci Rep; 2019 Oct; 9(1):14299. PubMed ID: 31586084
[TBL] [Abstract] [Full Text] [Related]
3. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
Li R; Gu J; Heymach JV; Shu X; Zhao L; Han B; Ye Y; Roth J; Wu X
Carcinogenesis; 2017 Apr; 38(4):419-424. PubMed ID: 28186269
[TBL] [Abstract] [Full Text] [Related]
